Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)
High Impact Clinical Trials ASN 2016
Howard Trachtman, Peter J. Nelson, Radko Komers
In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria.
As compared to irbesartan, urinary protein excretion was suppressed to a greater extent than blockade of angiotensin II alone. No hard clinical endpoints were evaluated.
- Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
- Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
- Proteinuria: Is the ONTARGET renal substudy actually off target?